S-Alpha Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series C
- Investors
-
14
S-Alpha Therapeutics General Information
Description
Developer of health applications and digital therapeutics designed to create a healthy and equitable society. The company offers treatment methods for disease areas including ophthalmology, neuropsychiatry, cancer, and immunology along with therapeutic devices and technologies and provides a digital approach for unmet medical needs, enabling patients to receive treatment for different diseases that are difficult to treat with current medical technology.
Contact Information
Website
www.salphadtx.comCorporate Office
- 311, Gangnam-daero
- 14th floor, Dream Plus
- Seoul, Seocho-gu
- South Korea
Corporate Office
- 311, Gangnam-daero
- 14th floor, Dream Plus
- Seoul, Seocho-gu
- South Korea
S-Alpha Therapeutics Timeline
S-Alpha Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 05-Nov-2025 | Completed | Clinical Trials - General | |||
| 5. Accelerator/Incubator | 29-Jul-2024 | Completed | Clinical Trials - General | |||
| 4. Early Stage VC (Series B) | 14-Mar-2023 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series A) | 04-Aug-2021 | Completed | Clinical Trials - General | |||
| 2. Seed Round | 20-Nov-2020 | $2.67M | $3.1M | Completed | Product Development | |
| 1. Corporate | 01-Feb-2020 | $428K | $428K | Completed | Product Development |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
S-Alpha Therapeutics Comparisons
Industry
Financing
Details
S-Alpha Therapeutics Competitors (4)
One of S-Alpha Therapeutics’s 4 competitors is GPCR Therapeutics, a Venture Capital-Backed company based in Seoul, South Korea.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GPCR Therapeutics | Venture Capital-Backed | Seoul, South Korea | ||||
| NovaSight | Venture Capital-Backed | Lod, Israel | ||||
| Dopavision | Venture Capital-Backed | Berlin, Germany | ||||
| Tilak | Venture Capital-Backed | Paris, France |
S-Alpha Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
S-Alpha Therapeutics Patents
S-Alpha Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025254452-A1 | System for providing customized myopia treatment using digital biomarkers and operating method thereof | Pending | 05-Jun-2024 | ||
| WO-2025135912-A1 | Digital device for treatment and management of trauma and stress-related disorders and method therefor | Inactive | 20-Dec-2023 | ||
| WO-2024262954-A1 | Eye activity promotion method using eye tracking that is independent from display size, and device therefor | Inactive | 20-Jun-2023 | ||
| WO-2024246605-A1 | Digital apparatus and application for treating vision asymmetry | Inactive | 26-May-2023 | ||
| JP-2025123266-A | Digital apparatus and application for improving eyesight | Pending | 03-Nov-2022 | A61H5/00 |
S-Alpha Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
S-Alpha Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kiwoom Investment | Venture Capital | Minority | ||
| LB Investment | Venture Capital | Minority | ||
| Mirae Asset Capital | Venture Capital | Minority | ||
| CJ Investment | Corporate Venture Capital | Minority | ||
| Devsisters Ventures | Corporate Venture Capital | Minority |
S-Alpha Therapeutics FAQs
-
When was S-Alpha Therapeutics founded?
S-Alpha Therapeutics was founded in 2019.
-
Where is S-Alpha Therapeutics headquartered?
S-Alpha Therapeutics is headquartered in Seoul, South Korea.
-
What is the size of S-Alpha Therapeutics?
S-Alpha Therapeutics has 20 total employees.
-
What industry is S-Alpha Therapeutics in?
S-Alpha Therapeutics’s primary industry is Drug Discovery.
-
Is S-Alpha Therapeutics a private or public company?
S-Alpha Therapeutics is a Private company.
-
What is S-Alpha Therapeutics’s current revenue?
The current revenue for S-Alpha Therapeutics is .
-
How much funding has S-Alpha Therapeutics raised over time?
S-Alpha Therapeutics has raised $20.2M.
-
Who are S-Alpha Therapeutics’s investors?
Kiwoom Investment, LB Investment, Mirae Asset Capital, CJ Investment, and Devsisters Ventures are 5 of 14 investors who have invested in S-Alpha Therapeutics.
-
Who are S-Alpha Therapeutics’s competitors?
GPCR Therapeutics, NovaSight, Dopavision, and Tilak are competitors of S-Alpha Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
